Skip to main content

G207

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

  • RegistryNCT03911388
  • PhasePhase 1
  • StatusRecruiting
  • ConditionNeoplasms, Brain
  • SponsorM.D. Anderson Cancer Center
How G207 worksNCT039113884 min

What the film says

Read the transcript

Most childhood brain tumors start in the cerebellum, low at the back of the head, where balance and coordination live. That is where medulloblastoma begins, the most common malignant brain tumor of childhood.

Treatment is a hard road: surgery, radiation to the whole brain and spine, then months of chemotherapy. Many children are cured, but it is tough on a growing brain. And when the tumor comes back after all of that, there are very few options left. That is the problem this trial is trying to solve.

Here is the idea. What if the treatment were a virus?

Almost everyone has met herpes simplex virus type one, the cold-sore virus. It is naturally good at getting into nerve cells. Scientists rebuilt it so it can grow inside cancer cells, but not healthy brain. The rebuilt virus is called G207. The strategy: let it do what viruses do, only inside the tumor, and let the immune system notice.

How does it work? Two edits to the virus's genes.

The first edit takes away the virus's key. Every healthy cell has an alarm: when it senses a virus, an enzyme called PKR shuts down the cell's protein factory, and the infection stalls. Natural herpes carries a gene that switches that alarm off. Scientists deleted it. Now healthy cells stop G207. But many cancer cells disabled that alarm on their way to becoming cancer. Inside them, G207 multiplies.

The second edit takes away a tool. To copy itself, the virus needs an enzyme that builds DNA. Scientists broke the virus's own copy, so G207 must borrow it from the cell it is in, and only dividing cells have it. Tumor cells divide constantly. Most mature brain cells do not.

Together, the two edits mean the virus can only thrive in the tumor. It multiplies inside cancer cells until they burst, spreads to the cancer cells next door, and all that debris draws in the immune system.

That last part may matter most. In the first trial of G207 in children, biopsies before treatment showed almost no immune cells in the tumor, what doctors call a cold tumor. Months later, the same tumors were crowded with T cells. Twelve children were treated. No serious side effects were blamed on the virus, and median survival was twelve point two months, against a historical five point six. A small first study, not proof, published in the New England Journal of Medicine in twenty twenty-one.

One more piece. In the lab, a small dose of radiation makes tumor cells produce more of the very enzyme the virus lost, which helps it multiply. So most children in this trial get one low dose of radiation the day after the virus.

That first trial treated the upper brain. This one takes G207 to the cerebellum for the first time, after mouse studies showed it was safe there. Children and young adults from three to twenty-one whose cerebellar tumor has returned receive a single infusion of G207 through fine catheters placed in the tumor. The first question is safety; the second is dose. It is led by Gregory Friedman at M D Anderson, with sites in Houston, Birmingham, and St. Louis.

Everything in this film comes from the published record, and it is not medical advice.

Sources behind this film

Show 8 more sources

The drug

What is being tested.

Single dose of G207 infused through catheters into region(s) of tumor. If G207 is safe in the first cohort of patients, subsequent patients will receive a single dose of G207 infused through catheters into region(s) of tumor followed by a 5 Gy dose of radiation to the tumor (which includes progressive leptomeningeal disease or any site of gross tumor progressing in the brain parenchyma) within 24 hours of virus inoculation.

Outcomes for children with recurrent or progressive cerebellar malignant brain tumors are very poor, and there are a lack of effective salvage therapies once a patient fails standard treatments. G207 is an oncolytic herpes simplex virus-1 (HSV) that has been successfully engineered to introduce mutations in the virus that enable it to selectively replicate in and kill cancer cells, but not normal cells.

Replication of G207 in the tumor not only kills the infected tumor cells, but causes the tumor cell to act as a factory to produce new virus. These virus particles are released as the tumor cell dies, and can then proceed to infect other tumor cells in the vicinity, and continue the process of tumor kill.

The study

How the trial runs.

This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, will also be tested. Funding Source- FDA OOPD

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Age ≥ 36 months and < 22 years
  • Pathologically proven malignant cerebellar brain tumor (including medulloblastoma, glioblastoma multiforme, giant cell glioblastoma, anaplastic astrocytoma, primitive neuroectodermal tumor, ependymoma, atypical teratoid/rhabdoid tumor, germ cell tumor, or other high-grade malignant tumor) which is progressive or recurrent despite standard care including surgery, radiotherapy, and/or chemotherapy. A pathologically proven secondary malignant cerebellar tumor without curative treatment options is eligible.
  • A review of the MRI scan will be necessary to determine if the tumor location and size are such that the patient may be included in the study. The MRI scan must be reviewed and approved by the site neurosurgeon and/or study radiologist for enrollment. The following guidelines must be met: Lesion must be ≤ 3.0 cm in diameter and surgically accessible as determined by MRI. Larger tumors may be surgically debulked and treated if ≤ 3.0 cm after debulking. Tumor measurements should be confirmed on the Immunotherapy Response Assessment in Neuro-Oncology (iRANO) form or the institutional MRI report
  • Patients must have fully recovered from acute treatment-related toxicities of all prior chemotherapy, immunotherapy or radiotherapy prior to the date of G207 administration. All washout intervals below are measured relative to the date of G207 administration.
  • Myelosuppressive chemotherapy: patients must have received their last dose at least 3 weeks prior (or at least 6 weeks if nitrosurea) to G207 administration.
  • Monoclonal antibodies: patient must have received the last dose ≥ 21 days prior to G207 administration

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.